13. 9. 2024
Krka receives gold and silver innovation awards
2 min. read
To mark the occasion of Innovation Day, the Slovenian Chamber of Commerce and Industry (GZS) presented annual innovation awards for achievements to Slovenian companies. Krka’s researchers won the gold award for tapentadol prolonged-release tablets for relief of severe pain, and the silver award for dabigatran used to treat and prevent thromboembolic events. The awards confirm that Krka with their outstanding experts, top-notch technology, and innovative solutions quickly and steadily supply innovative, quality, safe, efficacious and affordable medicines for the broadest range of patients.
Gold award for medication for relieving severe pain
A gold award went to Krka experts who, by using innovative solutions, developed quality, safe, and efficacious medicine containing tapentadol in the form of tapentadol maleate in innovative pharmaceutical prolonged-release form for relieving severe chronic pain. The active substance was incorporated in prolonged-release tablets preventing non-medicinal use. We integrate sustainable solutions in all stages of product development and production that are used to systematically reduce the environmental impact. This innovation has facilitated the early launch of a more affordable medication.
Silver award for medication used to treat and prevent thromboembolic events
A silver award was presented to Krka researchers for the medication containing dabigatran which significantly improves the possibilities for the treatment and prevention of dangerous thromboembolic events. By way of innovations in the synthesis of the active ingredient and in the finished product, they resolved challenges owing to unfavourable properties of the active substance, and developed a safe, efficacious and high-quality medicine. Optimised manufacturing procedures enable its uninterrupted availability, accessibility and minimal environmental impact.
Our most significant sustainable concerns include product quality and patient safety
At this year’s ceremony held under the title ‘We have chosen sustainability’, national accolades were awarded for the 22nd year in a row to most innovative companies and other organisations. In the professional part of the programme, Dr Aleš Rotar, member of the Management Board and Director of Pharmaceutical R&D and Production, and Dr Zvone Simončič, Director of Pharmaceutical R&D, discussed key challenges of developing modern generic pharmaceuticals at Krka and the significance of innovation in pharmaceutical industry.